AstraZeneca reports positive Phase III stomach cancer drug results
AstraZeneca reported on 2026-10-25 that Sone-Ve met the overall-survival endpoint in the Phase III CLARITY-Gastric01 trial for advanced, CLDN18.2-positive gastrointestinal cancers. In the 2L+ population, median overall survival was 10.6 months versus 6.4 months for investigator's choice, while the 3L+ analysis showed 10.0 months versus 5.0 months. Progression-free survival assessed by blinded independent central review improved numerically but did not reach statistical significance.
Why it matters
The overall-survival data give AstraZeneca clinical evidence for potential regulatory filings, but regulatory submissions remain pending. The result could expand Sone-Ve's addressable treatment population if later filings and reviews succeed.
Key facts
- 1In the 2L+ population, Sone-Ve produced median overall survival of 10.6 months versus 6.4 months for investigator's choice, with an HR of 0.58. stocktitan.net
- 2In the 3L+ population, median overall survival was 10.0 months versus 5.0 months, with an HR of 0.47 and p<0.000001. stocktitan.net
- 3BICR-assessed median PFS was 4.2 months versus 3.8 months, with an HR of 0.77 and p=0.053193, which did not reach statistical significance. stocktitan.net
- 4The trial included 545 patients across 19 countries. stocktitan.net
Open questions
- The estimate of potential annual sales of $5 billion appears only in material 4 and is not independently corroborated by the other materials.
- Material 3 describes the data as potentially registrational, but the materials do not confirm that AstraZeneca has filed for regulatory approval.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.